Royalty Pharma officer proposes $17.6M share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc (RPRX) officer Terrance Coyne’s Form 144 notice covers a proposed sale of 257,122 common shares, with an aggregate market value of $17,619,285.05 and an approximate sale date of November 16, 2026. The notice says the sales are made in connection with a selling plan dated August 6, 2026, intended to comply with Rule 10b5-1(c).
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.